300289 Beijing Leadman Biochemistry
- 4.56
- +0.08+1.79%
Beijing Leadman Biochemistry News
Leadman (300289.SZ): The business does not currently involve proteasomes
Glonghui May 30 丨 Some investors asked Leadman (300289.SZ) on the investor interactive platform, “Does your company have proteasomes or layout?” The company replied that the company's business does not currently involve proteasomes.
Leadman (300289.SZ): There are currently no plans to directly invest in or acquire Yixi Biotech
On May 13, Ge Longhui | Leadman (300289.SZ) said on the investor interactive platform that the company's products in the field of immunotesting mainly include chemiluminescence kits and related diagnostic instruments. The company currently has no plans to directly invest in or acquire Yixi Biotech.
Leadman (300289.SZ) 2023 equity distribution: 0.1 yuan for every 10 shares, shares registered on May 16
Leadman (300289.SZ) issued an announcement. The company's 2023 equity distribution plan is: Based on the company's existing...
Leadman (300289.SZ): Enzyme products are currently mainly used in the development and production of biochemical diagnostic reagents
Gelonghui, May 8 | Leadman (300289.SZ) said on the investor interactive platform that the company's enzyme products are currently mainly used in the development and production of biochemical diagnostic reagents.
Leadman (300289.SZ): Not involved in the field of synthetic biology
Glonghui, May 6 | Leadman (300289.SZ) said on the investor interactive platform that the company is currently focusing on the in vitro diagnosis industry and has not yet involved the field of synthetic biology.
Leadman (300289.SZ): Net loss of 2.751 million yuan in the first quarter
Gelonghui, April 25 | Leadman (300289.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 94.6241 million yuan, down 12.51% year on year; net profit attributable to shareholders of listed companies - 27.51 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 4.8794 million yuan; basic earnings per share - 0.0050 yuan.
Leadman (300289.SZ): Currently, e-commerce platforms and cross-border e-commerce platform promotion channels are not involved
Gelonghui, April 8 | Leadman (300289.SZ) said on the investor interactive platform that at this stage, the company promotes products and brands through various forms such as online marketing, public account tweets, academic marketing, thematic salons, expert satellite meetings, product promotion conferences, etc., and is actively building celebrity classrooms and scientific research courses as academic leading platforms to increase the recognition and satisfaction of end users with the company's products through academic brand influence, so as to strengthen academic construction of benchmark hospitals and in-depth cooperation with KOL experts. Currently, e-commerce platforms are not involved. Promotion channels with cross-border e-commerce platforms
Leadman (300289.SZ): Net profit of 15.337 million yuan in 2023, plan to distribute 0.1 yuan to 10 shares
On March 27, GLONGHUI | Leadman (300289.SZ) released its 2023 annual report. Operating income was 460 million yuan, down 34.62% year on year, and net profit was 15.337 million yuan, reversal of year-on-year losses. After deducting non-net profit of 8.79 million yuan, reversing losses year-on-year, with basic earnings of 0.03 yuan per share. A cash dividend of 0.1 yuan is distributed to all shareholders for every 10 shares.
Leadman (300289.SZ): The R&D and production base has a production capacity of 250,000 liters of in vitro biochemical diagnostic reagents and 2,500 liters of in vitro immunodiagnostic reagents
Gelonghui, March 21丨Leadman (300289.SZ) said on the investor interactive platform that the company's R&D and production base has adopted high industry standards and has built a large-scale, advanced and efficient fully automated diagnostic reagent production line. The assembly line includes four parallel production lines, which fully automate the preparation, canning, labeling and packaging, and has a production capacity of 250,000 liters of in vitro biochemical diagnostic reagents and 2,500 liters of in vitro immune diagnostic reagents. After being awarded the “2018 Beijing Intelligent Manufacturing Benchmark Enterprise”, the company passed the “2022 Beijing Intelligent Manufacturing Benchmark Enterprise (Figure)
Leadman (300289.SZ): Joint Medical, a shareholder, has launched a fully automated fluorescent staining intelligent analysis system (Gis3000 series), which can provide intelligent morphological panoramic solutions for gynecological inflammation
Glonghui, March 21丨Leadman (300289.SZ) said on the investor interactive platform that United Medicine, in which the company invests, has launched a fully automated fluorescence staining intelligent analysis system (Gis3000 series), which can provide an intelligent morphological panoramic solution for gynecological inflammation. Full process automation combined with artificial intelligence AI technology can automatically smear, automatically dye, automatically dry, automatically focus, automatically scan, label, screen and output report functions for clinical use.
Leadman (300289.SZ): The current business focuses on the in vitro diagnosis industry and does not involve drugs
Gelonghui, March 15 | An investor asked Leadman (300289.SZ) on the investor interactive platform, “Please ask if your company has drugs with independent intellectual property rights developed through technical means such as chemical synthesis, genetic engineering, and antibody engineering.” The company replied that the company's current business focuses on the in vitro diagnosis industry and does not involve drugs.
Leadman (300289.SZ): Desai Systems obtained a medical device registration certificate for in vitro diagnostic reagents
On March 14, Gelonghui Leadman (300289.SZ) announced that Desai Diagnostic Systems (Shanghai) Co., Ltd. (“Desai System”), a wholly-owned subsidiary of the company, recently obtained an in vitro diagnostic reagent “Medical Device Registration Certificate” issued by the Shanghai Drug Administration. The free fatty acid determination kit (enzyme method) can accurately measure the level of free fatty acids in patients, providing strong support for early screening, diagnosis, and evaluation of treatment effects of diseases such as diabetes and cardiovascular disease.
Leadman (300289.SZ): The company is currently not involved in charging piles and new energy vehicles
GLONGHUI March 5 | Leadman (300289.SZ) said on the investor interactive platform that the company is currently not involved in charging stations and new energy vehicles.
Leadman (300289.SZ): The R&D and production base has a production capacity of 250,000 liters of in vitro biochemical diagnostic reagents and 2,500 liters of in vitro immunodiagnostic reagents
Gelonghui, March 1 | Leadman (300289.SZ) said on the investor interactive platform that the company's R&D and production base has adopted high industry standards and has built a large-scale, advanced and efficient fully automated diagnostic reagent production line. The assembly line includes four parallel production lines, which fully automate the preparation, canning, labeling and packaging, and has a production capacity of 250,000 liters of in vitro biochemical diagnostic reagents and 2,500 liters of in vitro immunological diagnostic reagents. The company has been awarded “2018 Beijing Intelligent Manufacturing Benchmark Enterprise” and “2022 Beijing Intelligent Manufacturing Benchmark Enterprise (Digital Workshop)
Leadman (300289.SZ): As of February 20, 2024, the number of shareholders in the company was 19,464
On February 26, GLONGHUI | Leadman (300289.SZ) said on the investor interactive platform that as of February 20, 2024, the number of shareholders of the company was 19,464.
Leadman (300289.SZ): Subsidiary Desai Systems has been re-certified as a high-tech enterprise
Gelonghui, Feb. 1 | Leadman (300289.SZ) announced that Desai Diagnostic Systems (Shanghai) Co., Ltd. (“Desai System”), a wholly-owned subsidiary of the company, recently received the “Second Batch of High-tech Enterprise Filing List for 2023 Accreditation Report by Shanghai Accreditation Agencies” issued by the National High-tech Enterprise Certification and Management Leading Group Office, confirming that Desai Systems has been re-certified as a high-tech enterprise and completed the filing. The high-tech enterprise certificate number is GR202331003815. The date of issue is December 12, 2023. Three years.
Leadman (300289.SZ): Expected net profit of 13 million yuan to 19 million yuan in 2023, turning a year-on-year loss into profit
On January 30, GLONGHUI | Leadman (300289.SZ) announced that it expects net profit of 13 million yuan to 19 million yuan in 2023, turning a year-on-year loss into a profit, deducting non-net profit of 5.17 million yuan to 11.17 million yuan, turning a year-on-year loss into a profit. In 2023, domestic hospital diagnosis and treatment activities resumed to focus on routine testing, and the company's overall revenue declined year-on-year. During the reporting period, the company carried out various operations and management tasks in an orderly manner according to the annual plan, actively responded to centralized procurement of biochemical reagents and industry changes, broadened sales channels, increased marketing efforts; optimized internal operation and management processes; and implemented cost reduction
Leadman (300289.SZ): There are currently no self-produced COVID-19 test reagent products
Gelonghui, January 22丨An investor asked Leadman (300289.SZ) on the investor interactive platform, “Are your company's COVID-19 testing products and antigen test kits effective against the currently popular JN.1? Are there technical barriers? What are the applications of biological reagent enzymes?” The company replied that biological reagent enzymes are mainly used in biochemistry, immunity, and molecular diagnosis. The company currently does not produce its own COVID-19 test reagent products.
Leadman (300289.SZ): The company has no chip business at this stage
GLONGHUI January 17 | Leadman (300289.SZ) said on the investor interactive platform that the company has no chip business at this stage. Microfluidic immune chip technology is an inspection technology different from existing chemiluminescence technology in the IVD industry. It has higher sensitivity, can directly detect whole blood, requires less sample, has a high degree of chip closure, low biological contamination, and is easy to operate, does not require washing or incubation, and is fast.
Leadman (300289.SZ): As of January 10, 2024, the number of shareholders of the company was 20,548
On January 11, GLONGHUI | Leadman (300289.SZ) said on the investor interactive platform that as of January 10, 2024, the number of shareholders of the company was 20,548.
Analysis
Price Target
No Data
